Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET
Company Participants
Darren Opland - Director, Corporate Communications
Herriot Tabuteau - CEO
Nick Pizzie - CFO
Ari Maizel - EVP and Head, Commercial
Mark Jacobson - Chief Operating Officer
Conference Call Participants
Jason Gerberry - Bank of America
Leonid Timashev - RBC Capital Markets
Charles Duncan - Cantor Fitzgerald
Cerena Chen - Wells Fargo
David Amsellem - Piper Sandler
Marc Goodman - Leerink Partners
Joseph Thome - TD Cowen
Myles Minter - William Blair
Poorna Kannan - Needham & Company
Joel Beatty - Baird
Graig Suvannavejh - Mizuho Securities
Matt Kaplan - Ladenburg Thalmann
Operator
Good morning, and welcome to the Axsome Therapeutics Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, there will be a question and answer session and instructions will be given at that time. Please note that today’s call is being recorded.
I will now turn the call over to Darren Opland, Director of Corporate Communications. Please go ahead sir.
Darren Opland
Thank you. Good morning, everyone and thank you for joining our third quarter 2024 financial results conference call. I am joined today by Dr. Herriot Tabuteau, Chief Executive Officer; Nick Pizzie, Chief Financial Officer; Mark Jacobson, Chief Operating Officer, and Ari Maizel, Chief Commercial Officer.
Earlier this morning, we posted a new corporate presentation complementing today’s call to the Investors Section of our website. Those joining by webcast may also again see the slides at any time during the discussion. As a reminder, we will be making certain forward-looking statements regarding, among other things, the efficacy, safety, and intended utilization of our investigational agents, our clinical and non-clinical plans, our plans to present or report additional data, the anticipated conduct and the source of future clinical trials, regulatory plans, future research and development plans, our commercial plans regarding Sunosi, Auvelity, and our pipeline products, revenue projections, and other financial forecasts if any, and the possible intended use of cash and investments.
These forward-looking statements are based on current information, assumptions, and expectations of future events and are subject to certain risks and uncertainties that may cause the company’s actual performance and results to differ materially from those projected. Please refer to today’s press release, presentation, and our SEC filings for additional details on these and important risk factors. You are cautioned not to rely on these forward-looking statements, which are only made as of today's date and the company disclaims any obligation to update or revise these statements.